Last reviewed · How we verify
Control group: Mesalazine enema treatment — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Control group: Mesalazine enema treatment (Control group: Mesalazine enema treatment) — Beijing Hospital of Traditional Chinese Medicine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Control group: Mesalazine enema treatment TARGET | Control group: Mesalazine enema treatment | Beijing Hospital of Traditional Chinese Medicine | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Control group: Mesalazine enema treatment CI watch — RSS
- Control group: Mesalazine enema treatment CI watch — Atom
- Control group: Mesalazine enema treatment CI watch — JSON
- Control group: Mesalazine enema treatment alone — RSS
Cite this brief
Drug Landscape (2026). Control group: Mesalazine enema treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/control-group-mesalazine-enema-treatment. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab